Literature DB >> 12802193

Selective deficit in no-go performance induced by blockade of prefrontal cortical alpha 2-adrenoceptors in monkeys.

Chao-Lin Ma1, Xue-Lian Qi, Ji-Yun Peng, Bao-Ming Li.   

Abstract

Two monkeys (Macaca mulatta) were trained to make a go response (go to touch a computer screen) when a red signal (go signal) was presented or a no-go response (inhibit the screen-touching action) when a green signal (no-go signal) was given. The alpha2-adrenergic antagonist yohimbine was infused locally, bilaterally and continuously for 8 days into the prefrontal cortex (PFC) by using mini-osmotic pump. The no-go but not go performance was selectively impaired during the 8-day administration of yohimbine: the monkeys showed an inability to inhibit the touching response to the no-go signal, indicating that there was a deficit in the inhibitory ability of the animals. Similar infusion of saline into the same cortical area was without effect. The present study provides behavioral pharmacological evidence that alpha2-adrenoceptors in the PFC are involved in the neural mechanisms underlying response inhibition.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12802193     DOI: 10.1097/01.wnr.0000070831.57864.7b

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  34 in total

Review 1.  The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder.

Authors:  Amy F T Arnsten
Journal:  Expert Rev Neurother       Date:  2010-10       Impact factor: 4.618

Review 2.  The role of neuromodulators in selective attention.

Authors:  Behrad Noudoost; Tirin Moore
Journal:  Trends Cogn Sci       Date:  2011-11-08       Impact factor: 20.229

Review 3.  Physiological approaches to understanding molecular actions on dorsolateral prefrontal cortical neurons underlying higher cognitive processing.

Authors:  Min Wang; Amy F T Arnsten
Journal:  Dongwuxue Yanjiu       Date:  2015-11-18

Review 4.  Adrenergic pharmacology and cognition: focus on the prefrontal cortex.

Authors:  Brian P Ramos; Amy F T Arnsten
Journal:  Pharmacol Ther       Date:  2006-12-28       Impact factor: 12.310

5.  Behavioral inhibition in mice bred for high vs. low levels of methamphetamine consumption or sensitization.

Authors:  Travis M Moschak; Katherine A Stang; Tamara J Phillips; Suzanne H Mitchell
Journal:  Psychopharmacology (Berl)       Date:  2012-02-04       Impact factor: 4.530

6.  Differences in cortical activity between methamphetamine-dependent and healthy individuals performing a facial affect matching task.

Authors:  Doris E Payer; Matthew D Lieberman; John R Monterosso; Jiansong Xu; Timothy W Fong; Edythe D London
Journal:  Drug Alcohol Depend       Date:  2007-10-26       Impact factor: 4.492

Review 7.  The neuropsychopharmacology of action inhibition: cross-species translation of the stop-signal and go/no-go tasks.

Authors:  Dawn M Eagle; Andrea Bari; Trevor W Robbins
Journal:  Psychopharmacology (Berl)       Date:  2008-06-10       Impact factor: 4.530

8.  The Emerging Neurobiology of Attention Deficit Hyperactivity Disorder: The Key Role of the Prefrontal Association Cortex.

Authors:  Amy F T Arnsten
Journal:  J Pediatr       Date:  2009-05-01       Impact factor: 4.406

Review 9.  Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction.

Authors:  Amy F T Arnsten
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

10.  Dopaminergic and noradrenergic contributions to functionality in ADHD: the role of methylphenidate.

Authors:  Veronika Engert; Jens C Pruessner
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.